



Medication Error Bulletin

Brought to you by Pharmacy Department, HCTM | Volume 13, March 2024

COMMON PRESCRIBING/TRANSCRIPTION ERRORS

PRESCRIBING MULTIPLE ORAL ANTICOAGULANT & ANTIPLATELETS

ANTICOAGULANTS

Case examples of error:

Mr XY is prescribed with both:

- Tab. Dabigatran 150mg BD
- Tab. Rivaroxaban 20mg OD.

Ms XX is prescribed with both:

- Tab. Edoxaban 60mg OD
- Tab. Apixaban 5mg BD

CONSEQUENCE

Drug interaction: Major Severity



Since the drugs mentioned are all anticoagulants, the anticoagulant effect will be enhanced if given more than one anticoagulant. Only one anticoagulant should be prescribed for a patient.

ANTIPLATELETS

Case example of error:

Mr PXY is prescribed 3 antiplatelets:

- Cardiprin (Aspirin) 1 tab OD
- Clopidogrel 75mg OD
- Ticagrelor 90mg BD

CONSEQUENCE

POTENTIAL OF BLEEDING!



Drug interaction: Moderate Severity 2 types of antiplatelets can be in dual

therapy but not 3 at once. Three antiplatelets will increase risk of bleeding.

HOW TO PREVENT SUCH ERRORS?

If an anticoagulant or antiplatelet is prescribed;

- 1. Don't copy and paste or just click "copy old meds" without checking for duplicates.
- 2. Double check old medications (Check which OAC patient was on)
- 3. Confirm which anticoagulant is of choice and stick to one

COMMON DUAL ANTIPLATELET COMBINATION:

ASPIRIN + CLOPIDOGREL (E.G. CARDIPRIN®) (E.G. PLAVIX®)

USUAL INDICATIONS FOR DUAL ANTIPLATELET OR TRIPLE THERAPY

DUAL ANTIPLATELET THERAPY/DAPT (ASPIRIN + 1 P2Y12 INHIBITOR)

Acute coronary syndrome or percutaneous coronary intervention (PCI) with stent insertion

TRIPLE THERAPY (DAPT + 1 NEW ANTICOAGULANT) **RECOMMENDED DURATION: 7-30 DAYS**

Atrial fibrillation + Acute coronary syndrome or percutaneous coronary intervention with stent insertion

EXAMPLE: ASPIRIN 100MG OD + CLOPIDOGREL 75MG OD + DABIGATRAN 150MG BD

Antiplatelets	
COX inhibitor	P2Y12 inhibitors
Aspirin	Clopidogrel Ticagrelor Ticlopidine

Anticoagulants	
Old generation	New generation
Warfarin	Apixaban
	Edoxaban
	Rivaroxa <mark>ban</mark>
	Dabigatran

References: 1. Daniel Shmyr et. al, Triple antithrombotic therapy for AF a Coronary Stents, 2017 PDF version of this bulletin can be found at https://hctm.ukm.my/farmasi/

2. European Society of Cardiology Guidelines 2020 for the diagnosis and management of AF

Produced by: Leanne Lew Hwui Ser leannelew@ppukm.ukm.edu.my

Contributors: Michelle Tan Hwee Pheng Nur Hafiza Saripin

hptan@ppukm.ukm.edu.my nurhafiza@ppukm.ukm.edu.my

This ME Bulletin is an intellectual property of PPUKM Pharmacy Department. All rights reserved. No part of this document may be reproduced, stored in the retrieval system or transmitted in any from by any means of electronic, mechanical, photocopying, recording or otherwise without prior written permission from PPUKM Pharmacy Department. Any use of the event names, photos or concepts presented in this document without an advanced written permission would be considered a violation of copyright.